Comparative Pharmacology
Head-to-head clinical analysis: ADZENYS ER versus AMPHETAMINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADZENYS ER versus AMPHETAMINE SULFATE.
ADZENYS ER vs AMPHETAMINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADZENYS ER is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
Increases presynaptic release of dopamine and norepinephrine, blocks reuptake, and inhibits monoamine oxidase, resulting in CNS stimulation.
Adults: Initial 5-10 mg orally once daily; titrate in 5-10 mg increments weekly to optimal response; max 60 mg/day.
5–60 mg/day orally in 1–3 divided doses, initial 5 mg once or twice daily, increase by 5 mg weekly.
None Documented
None Documented
6-8 hours in adults; in children 3-6 hours, requiring twice-daily dosing for sustained effect
Terminal elimination half-life: 10-13 hours in adults with acidic urine; prolonged to 16-34 hours with alkaline urine. In children, half-life is typically shorter (6-8 hours).
70% renal (30% unchanged, 40% as metabolites), 30% fecal/biliary
Renal excretion of unchanged amphetamine (approximately 30-40%) and its metabolites; urinary pH-dependent: acidic urine enhances elimination (up to 70% unchanged), alkaline urine reduces it. Minor biliary/fecal elimination (<10%).
Category C
Category D/X
CNS Stimulant
CNS Stimulant